1. Search Result
Search Result
Results for "

Gram-positive Staphylococcus aureus strains

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

1

Peptides

14

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103249

    Reutericycline

    Bacterial Infection Metabolic Disease
    Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections .
    Reutericyclin
  • HY-126858

    (+)-Ambuic acid

    ERK JNK NO Synthase COX Infection Inflammation/Immunology
    Ambuic acid exhibits antimicrobial activity against Staphylococcus aureus, with IC50 of 43.9 μM for strain ATCC 6538. Ambuic acid is an inhbitor for the biosynthesis of cyclic peptide quorum sensing molecules (quormones) in gram-positive bacteria. Ambuic acid exhibits anti-inflammatory activity through ERK/JNK/MAPK signaling pathway .
    Ambuic acid
  • HY-116271

    Antibiotic Bacterial Infection
    Sperabillin C is an antibacterial antibiotic with activity against both Gram-negative and Gram-positive bacteria, including resistant strains of Pseudomonas aeruginosa and Staphylococcus aureus .
    Sperabillin C
  • HY-121348

    U-47929

    Antibiotic Bacterial DNA/RNA Synthesis Infection
    Ficellomycin is a nitrogen-containing bicyclic antibiotic with strong activity against Gram-positive bacteria, including multidrug-resistant strains of Staphylococcus aureus. Ficellomycin works by inducing the formation of defective 34S DNA fragments, which interfere with the semi-conservative DNA replication process. These fragments lack the ability to integrate into larger DNA segments and eventually form a complete bacterial chromosome. Ficellomycin can be used in research for various bacterial diseases .
    Ficellomycin
  • HY-178952

    Bacterial Infection
    Anti-infective agent 12 (Compound A09) is a competitive inhibitor of type I signal peptidease (SPase I), with an IC50 of 4.475 μM and a Kd of 16.3 μM. Anti-infective agent 12 has the ability to disrupt bacterial membranes and remove biofilms. Anti-infective agent 12 exhibits potent bactericidal activity against Gram-positive bacteria, with MIC values of 4, 4, 8, and 8 μg/mL for Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, and Streptococcus suis, respectively. Anti-infective agent 12 remains effective against multi-drug resistant strains, but has weaker activity against Gram-negative bacteria (such as Escherichia coli and Salmonella), with MIC values > 64 μg/mL. Anti-infective agent 12 has low hemolytic activity and shows significant efficacy in mouse skin infection models .
    Anti-infective agent 12
  • HY-N14706

    Bacterial Infection
    Kibdelin A is resistant to Gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as Vancomycin (HY-B0671) .
    Kibdelin A
  • HY-N14707

    Bacterial Infection
    Kibdelin B is resistant to Gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as Vancomycin (HY-B0671) .
    Kibdelin B
  • HY-N14710

    Bacterial Infection
    Kibdelin D is resistant to Gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as Vancomycin (HY-B0671) .
    Kibdelin D
  • HY-N14709

    Bacterial Infection
    Kibdelin C2 is resistant to Gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as Vancomycin (HY-B0671) .
    Kibdelin C2
  • HY-N14708

    Bacterial Infection
    Kibdelin C1 is resistant to Gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as Vancomycin (HY-B0671) .
    Kibdelin C1
  • HY-N14955

    Antibiotic Bacterial Infection
    3-O-α-D-Forosaminyl-(+)-griseusin is a memberof naphthoquinone antibiotic. 3-O-α-D-Forosaminyl-(+)-griseusin is active against Gram-positive bacteria including methicillin-resistant strain of Staphylococcus aureus (MRSA) .
    3-O-α-D-Forosaminyl-(+)-griseusin
  • HY-160669

    Bacterial Infection
    Antibacterial agent 198 (Compound 16) is an antibacterial agent against gram positive Staphylococcus aureus and strains of Entercoccus .
    Antibacterial agent 198
  • HY-125524

    Bacterial Infection
    Antibacterial agent 199 (Compound 2) is an activator for caseinolytic protease (ClpP) with a Kd of 0.7 μM. Antibacterial agent 199 exhibits antibacterial efficacy against Gram-positive strains Staphylococcus aureus, Streptococcus pneumoniae and Gram-negative strain Neisseria meningitidis, with MICs of 16, 0.5 and 0.5 μg/mL, respectively .
    Antibacterial agent 199
  • HY-113703

    Antibiotic Cancer
    PD117588 is a quinolone antibacterial agent with a broad range of antibacterial activity. PD117588 exhibits excellent activity against a variety of Gram-positive and Gram-negative bacteria from cancer patients, especially against all Gram-positive strains, including methicillin-resistant Staphylococcus aureus, coagulase-negative Staphylococci, and Enterococci. PD117588 is also very effective against most Gram-negative bacilli, although ciprofloxacin shows stronger activity against Pseudomonas aeruginosa. Compared with other quinolone antibiotics, the minimum inhibitory concentration of PD117588 outperforms most of the tested microorganisms, including imipenem and ceftazidime .
    PD117588
  • HY-W034984

    Bacterial Infection
    (1,5-Cyclooctadiene) dimethylplatinum (II) (Compound Pt3) is an Antibacterial agent. (1,5-Cyclooctadiene) dimethylplatinum (II) exhibits limited but selective activity against some Gram-positive Staphylococcus aureus strains, including methicillin-resistant Staphylococcus aureus (MRSA) and Glycopeptide-intermediate Staphylococcus aureus (GISA). (1,5-Cyclooctadiene) dimethylplatinum (II) shows no hemolytic activity .
    (1,5-Cyclooctadiene)dimethylplatinum(II)
  • HY-14780

    NXL 101

    Antibiotic Topoisomerase DNA/RNA Synthesis Bacterial Infection
    Viquidacin (NXL 101) is an antibiotic with inhibitory activity against topoisomerase IV and DNA gyrase. Viquidacin exhibits antibacterial activity against gram positive bacterial by inhibiting the supercoiling, decatenation and relaxation in strains Staphylococcus aureus and Escherichia coli in micromolar levels. Viquidacin inhibits S. aureus wildtype and mutants with MIC of 2-128 mg/L .
    Viquidacin
  • HY-181820

    Topoisomerase DNA Glycosylase Bacterial Infection
    Topoisomerase IV-IN-3 is a Staphylococcus aureus Topoisomerase IV inhibitor, DNA gyrase inhibitor and antibacterial agent. Topoisomerase IV-IN-3 has IC50 values of 1.32 μM and 0.48 μM against topoisomerase IV, and 0.88 μM and 0.54 μM against DNA gyrase. Topoisomerase IV-IN-3 inhibits decatenation, ATPase, and supercoiling activities of its target enzymes. Topoisomerase IV-IN-3 exerts antibacterial activity against Gram-positive and Gram-negative bacterial strains. Topoisomerase IV-IN-3 exhibits low cytotoxicity toward human fibroblast cells. Topoisomerase IV-IN-3 can be used for the research of bacterial infections .
    Topoisomerase IV-IN-3
  • HY-N18878

    Bacterial Endogenous Metabolite Parasite Infection
    Ambigol C is an ambigol, Antibacterial agent and Antimalarial agent. Ambigol C is isolated from Fischerella ambigua 108b. Ambigol C exhibits selective antibacterial activity against Gram-positive Staphylococcus aureus strains (including MRSA) with MIC values of 0.98-3.91 μg/mL. Ambigol C also shows potent antibacterial activity against B. megaterium, and possesses weak antimalarial and trypanocidal effects. Ambigol C can be used in the research of bacterial infections, plasmodial infections and trypanosomal infections .
    Ambigol C
  • HY-185351

    Ampicillin/Sulbactam combination

    Bacterial Antibiotic Infection
    Ampicillin sodium and Sulbactam sodium are formed by mixing HY-B0522A Ampicillin sodium with HY-B0334A Sulbactam sodium (each 1.5 g of this product contains 1 g amoxicillin sodium and 0.5 g sulbactam sodium). Ampicillin is a β-lactam antimicrobial, whereas sulbactam is a β-lactamase inhibitor. Ampicillin has a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria. However, ampicillin is degraded by beta-lactamases. The combination of ampicillin and sulbactam demonstrates synergy in addressing bacterial strains resistant to ampicillin, thus providing broader coverage. Bacteria susceptible to ampicillin/sulbactam include Haemophilus influenzae, Escherichia coli, Acinetobacter, Klebsiella, Staphylococcus aureus, Enterobacter, and anaerobes.
    Ampicillin sodium and Sulbactam sodium
  • HY-P11657

    Bacterial Infection
    GN-2 peptoid is a 9-mer cationic amphipathic peptoid and bactericidal agent with an overall net charge of +4, broad-spectrum antimicrobial activity, and low hemolytic and cytotoxic activity against mammalian cells. GN-2 peptoid exerts bactericidal action against Escherichia coli in a concentration-dependent manner. GN-2 peptoid exhibits antimicrobial activity against Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli, Pseudomonas aeruginosa strains. GN-2 peptoid shows low toxicity against human red blood cells and HeLa cells. GN-2 peptoid maintains antimicrobial activity in the presence of 50% human blood plasma. GN-2 peptoid can be used for the research of bacterial infections .
    GN-2 peptoid
  • HY-181819

    Bacterial Topoisomerase Infection
    Antibacterial agent 327 (Compound 6f) is an Antibacterial agent. Antibacterial agent 327 potently inhibits the supercoiling activity of Staphylococcus aureus DNA gyrase with an IC50 of 0.28 μM. It also inhibits the ATPase activities of DNA gyrase and Topoisomerase IV, as well as the decatenation activity of Topoisomerase IV (IC50: 0.43 μM, 0.73 μM, and 2.31 μM, respectively). Antibacterial agent 327 potently inhibits Clostridioides difficile and methicillin-resistant Staphylococcus aureus (HY-121544), with an MIC of 0.78 μg/mL for both. Antibacterial agent 327 inhibits Escherichia coli with an MIC50 of 0.78 μg/mL .
    Antibacterial agent 327
  • HY-149456

    Bacterial Infection
    Xanthoangelol F is a prenylated (geranylated) chalcone and Antibacterial agent. Xanthoangelol F can be isolated from Angelica keiskei. Xanthoangelol F inhibits the growth of Gram-positive bacteria Bacillus subtilis, Staphylococcus epidermidis, and Micrococcus luteus, with an MIC of 64 μg/mL .
    Xanthoangelol F
  • HY-182027

    Bacterial Reactive Oxygen Species (ROS) Lactate Dehydrogenase DNA/RNA Synthesis Infection
    Antibacterial agent 330 is an antibacterial agent. Antibacterial agent 330 triggers ROS accumulation, forms DNA supramolecular complex by intercalation to block DNA replication and inhibits LDH to
    disturb metabolism, and further prompts bacterial cell rupture to induce the leakage of intracellular content, ultimately causing bacterial death. Antibacterial agent 330 displays antibacterial activity and promotes wound healing in both G. Mellonella larval and murine wound infection models. Antibacterial agent 330 can be used for the research of bacterial infections .
    Antibacterial agent 330
  • HY-183782

    Antibiotic Bacterial Infection
    SA1103064 is a potent antibiotic with antibacterial activity against multiple resistant bacterial strains. SA1103064 binds to the bacterial ribosome's nascent peptide exit tunnel. SA1103064 can be used for the research of bacterial infections .
    SA1103064
  • HY-N13838

    Bacterial Infection
    8,9-Dehydro-7,9-diisobutyryloxythymol is a Thymol (HY-N6810) derivative, as well as an antibacterial agent. 8,9-Dehydro-7,9-diisobutyryloxythymol can be found in the aerial parts of Ageratina adenophora, with selective activity against Gram-positive bacterial strains including Bacillus cereus. 8,9-Dehydro-7,9-diisobutyryloxythymol does not exhibit detectable in vitro cytotoxic activity against human cancer cell lines. 8,9-Dehydro-7,9-diisobutyryloxythymol can be used for the research of bacterial infection .
    8,9-Dehydro-7,9-diisobutyryloxythymol
  • HY-W077690

    Bacterial Infection
    3-(2-Hydroxyethyl)quinazoline-2,4(1H,3H)-dione is an metal chelating agent and anti-bacterial agent. 3-(2-Hydroxyethyl)quinazoline-2,4(1H,3H)-dione shows inhibitory activity against gram-positive and gram-negative bacterial strains .
    3-(2-Hydroxyethyl)quinazoline-2,4(1H,3H)-dione
  • HY-181674

    Aminopeptidase Bacterial Infection
    ZHO-197 is a dual bacterial peptide deformylase and methionine aminopeptidase inhibitor with antibacterial activity. ZHO-197 exhibits an Escherichia coli peptide deformylase IC50 of 0.021 μM and a human peptide deformylase IC50 of 3.289 μM. ZHO-197 displays broad-spectrum antibacterial activity against gram-positive and gram-negative bacterial strains. ZHO-197 can be used for the research of bacterial infection .
    ZHO-197
  • HY-181100

    Dihydrofolate reductase (DHFR) Bacterial Infection
    DHFR-IN-26 is an Escherichia coli dihydrofolate reductase (ecDHFR) inhibitor with an IC50 of 0.75 nM. DHFR-IN-26 exerts broad-spectrum antibacterial activity. DHFR-IN-26 disrupts folate metabolism, nucleotide synthesis, and bacterial amino acid metabolic pathways. DHFR-IN-26 disrupts bacterial inner membranes, inhibited biofilm formation, and attenuated phage-related processes. DHFR-IN-26 shows lower toxicity to non-cancerous cells. DHFR-IN-26 can be used for the research of bacterial infections (including infections caused by methicillin-resistant Staphylococcus aureus, multidrug-resistant Escherichia coli, multidrug-resistant Pseudomonas aeruginosa, and lysogenic bacteria) .
    DHFR-IN-26
  • HY-102072

    Bacterial DNA/RNA Synthesis Infection
    GKL003 is a bacterial transcription inhibitor that targets the RNAP-σ interaction interface, with a Ki of 5.79 nM. GKL003 specifically binds to the RNAP β' clamp helix region at the σ A factor binding site, blocks the formation of RNAP holoenzyme, and inhibits the formation of bacterial transcription initiation complexes. GKL003 inhibits the growth of both Gram-positive and Gram-negative bacterial cells, and also exhibits activity against drug-resistant strains .
    GKL003

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: